Genetic variation in PEAR1 is thus considered a critical determinant of residual platelet function during aspirin treatment and might be a crucial determinant of residual platelet function during antiplatelet therapy [11,14], thereby affecting the clinical outcomes of stroke and TIA patients. Here, PEAR1 is linked to transient ischemic attack.